BACKGROUND: The purpose of this study was to assess the efficacy and toxicity of biweekly irinotecan plus 5-fluorouracil (FU) and leucovorin (LV) in patients with relapsed or metastatic colorectal cancer. MATERIALS AND METHODS: Between March 2002 and May 2004, 24 patients with histologically confirmed relapsed or metastatic colorectal cancer were enrolled in this study. One chemotherapy cycle consisted of irinotecan 180 mg/m(2) on days 1 and 15; 5-FU 400 mg/m(2) bolus IV with 600 mg/m(2) by a 22 hour intravenous infusion on days 1, 2, 15 and 16; and leucovorin 20 mg/m(2) on days 1, 2, 15 and 16, every 4 weeks. RESULTS: The median age of the 24 was 57.5 years (range, 38 approximately 69). Their metastatic sites included: the liver (62.5%), lung (20.8%), peritoneum (16.7%), lymph node (12.5%), ovary (8.3%) and pelvis/vagina (8.3%). Twenty-two patients were evaluable for a response. Six and 7 patients achieved partial responses and stable diseases, respectively. The overall response rate was 27.3% (95% Confidence interval; 10.3 approximately 44.5%). The median follow-up duration for surviving patients was 14.7 months (range, 1.7 approximately 26.5). Median overall survival (OS) and 1-year OS rates were 19 months and 86.3%, respectively. Median response duration and median progression free survival were 7.47 and 5.57 months, respectively. A total of 83 cycles (median 4 cycles) were administered. The main non-hematologic toxicities were nausea/vomiting (44.5%/18.1%) and diarrhea (8.4%). The most common hematologic toxicity was NCI grade I/II anemia (31.3%) and grade I/II neutropenia was 10.8%. There was no life-threatening toxicity. CONCLUSION: The results suggested that irinotecan, 5-FU and leucovorin combination chemotherapy in a biweekly schedule is a practical and tolerable treatment option in patients with advanced colorectal cancer.
BACKGROUND: The purpose of this study was to assess the efficacy and toxicity of biweekly irinotecan plus 5-fluorouracil (FU) and leucovorin (LV) in patients with relapsed or metastatic colorectal cancer. MATERIALS AND METHODS: Between March 2002 and May 2004, 24 patients with histologically confirmed relapsed or metastatic colorectal cancer were enrolled in this study. One chemotherapy cycle consisted of irinotecan 180 mg/m(2) on days 1 and 15; 5-FU 400 mg/m(2) bolus IV with 600 mg/m(2) by a 22 hour intravenous infusion on days 1, 2, 15 and 16; and leucovorin 20 mg/m(2) on days 1, 2, 15 and 16, every 4 weeks. RESULTS: The median age of the 24 was 57.5 years (range, 38 approximately 69). Their metastatic sites included: the liver (62.5%), lung (20.8%), peritoneum (16.7%), lymph node (12.5%), ovary (8.3%) and pelvis/vagina (8.3%). Twenty-two patients were evaluable for a response. Six and 7 patients achieved partial responses and stable diseases, respectively. The overall response rate was 27.3% (95% Confidence interval; 10.3 approximately 44.5%). The median follow-up duration for surviving patients was 14.7 months (range, 1.7 approximately 26.5). Median overall survival (OS) and 1-year OS rates were 19 months and 86.3%, respectively. Median response duration and median progression free survival were 7.47 and 5.57 months, respectively. A total of 83 cycles (median 4 cycles) were administered. The main non-hematologic toxicities were nausea/vomiting (44.5%/18.1%) and diarrhea (8.4%). The most common hematologic toxicity was NCI grade I/II anemia (31.3%) and grade I/II neutropenia was 10.8%. There was no life-threatening toxicity. CONCLUSION: The results suggested that irinotecan, 5-FU and leucovorin combination chemotherapy in a biweekly schedule is a practical and tolerable treatment option in patients with advanced colorectal cancer.
Entities:
Keywords:
5-Fluorouracil; Irinotecan; Leucovorin; Metastatic colorectal cancer
Authors: H C Pitot; D B Wender; M J O'Connell; G Schroeder; R M Goldberg; J Rubin; J A Mailliard; J A Knost; C Ghosh; R J Kirschling; R Levitt; H E Windschitl Journal: J Clin Oncol Date: 1997-08 Impact factor: 44.544
Authors: E Van Cutsem; D Cunningham; W W Ten Bokkel Huinink; C J Punt; C G Alexopoulos; L Dirix; M Symann; G H Blijham; P Cholet; G Fillet; C Van Groeningen; J M Vannetzel; F Levi; G Panagos; C Unger; J Wils; C Cote; C Blanc; P Hérait; H Bleiberg Journal: Eur J Cancer Date: 1999-01 Impact factor: 9.162
Authors: M L Rothenberg; J V Cox; R F DeVore; J D Hainsworth; R Pazdur; S E Rivkin; J S Macdonald; C E Geyer; J Sandbach; D L Wolf; J S Mohrland; G L Elfring; L L Miller; D D Von Hoff Journal: Cancer Date: 1999-02-15 Impact factor: 6.860
Authors: M Ducreux; M Ychou; J F Seitz; M Bonnay; A Bexon; J P Armand; M Mahjoubi; D Méry-Mignard; P Rougier Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: P Rougier; R Bugat; J Y Douillard; S Culine; E Suc; P Brunet; Y Becouarn; M Ychou; M Marty; J M Extra; J Bonneterre; A Adenis; J F Seitz; G Ganem; M Namer; T Conroy; S Negrier; Y Merrouche; F Burki; M Mousseau; P Herait; M Mahjoubi Journal: J Clin Oncol Date: 1997-01 Impact factor: 44.544
Authors: L B Saltz; J Kanowitz; N E Kemeny; L Schaaf; D Spriggs; B A Staton; R Berkery; C Steger; M Eng; A Dietz; P Locker; D P Kelsen Journal: J Clin Oncol Date: 1996-11 Impact factor: 44.544
Authors: M L Rothenberg; J R Eckardt; J G Kuhn; H A Burris; J Nelson; S G Hilsenbeck; G I Rodriguez; A M Thurman; L S Smith; S G Eckhardt; G R Weiss; G L Elfring; D A Rinaldi; L J Schaaf; D D Von Hoff Journal: J Clin Oncol Date: 1996-04 Impact factor: 44.544
Authors: J A Conti; N E Kemeny; L B Saltz; Y Huang; W P Tong; T C Chou; M Sun; S Pulliam; C Gonzalez Journal: J Clin Oncol Date: 1996-03 Impact factor: 44.544
Authors: In Ja Park; Hee Cheol Kim; Chang Sik Yu; Heung Moon Chang; Jea Hwan Lee; Jong Hoon Kim; Tae Won Kim; Jung Sun Kim; Jin Cheon Kim Journal: Cancer Res Treat Date: 2004-12-31 Impact factor: 4.679